Elutia Inc. ELUT
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- +16.88%
- 1 year
- +22.91%
- Market cap
- 35.96M
- Revenue (ttm)
- 24.99M
- Profit margin
- -261.08%
- EPS (ttm)
- -0.68
- Shares out
- 30.25M
- Forward P/E
- -3.98
- YTD return
- +16.88%
- 1-year return
- +22.91%
- Volume
- 20.73K
- Avg volume
- 184.34K
- Open
- 0.835
- Previous close
- 0.83
- Day's range
- 0.8051 – 0.8384
- 52-week range
- 0.50 – 1.39
- Beta
- 0.76
- Price target
- 9.00 (+1011.1%)
Key statistics
- 50-day average
- 3.86
- 200-day average
- 3.63
- Enterprise value
- 125.88M
- Price / sales
- 6.06
- Revenue growth
- -0.90%
- Free cash flow
- 490.13K
- Total cash
- 18.19M
- Total debt
- 22.81M
- Short % of float
- 0.54%
Fundamental scorecard
10 of 25 checks passed on ELUT’s reported financials
10of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 2 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.33 | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | -1.14 | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -0.75 | — | — |
| Mar 7, 2024 | Dec 1, 2023 | 0.00 | -0.66 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Sep 6, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 8, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
| Jun 21, 2024 | Lake Street | main | Buy | Buy |
| Jun 20, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
| Jun 18, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
About Elutia Inc.
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- elutia.com
News
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Elutia Inc. (ELUT) Q3 2026 Earnings Call Transcript
Elutia Q3 2026 Earnings Call Transcript
Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Financial Analysis: Elutia (NASDAQ:ELUT) & QuidelOrtho (NASDAQ:QDEL)
Analyzing Elutia (NASDAQ:ELUT) and Edwards Lifesciences (NYSE:EW)
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
Jushi (OTCMKTS:JUSHF) vs. Elutia (NASDAQ:ELUT) Head-To-Head Survey
Your note
Sign in to keep a note on ELUT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIRCHVIEW CAPITAL, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 26, 2023 | 0 |
| ENGLESE THOMAS | Officer | Sale | Mar 8, 2023 | 17,917 |
| FERGUSON MATTHEW B | Chief Financial Officer | Conversion of Exercise of derivative security | Dec 9, 2024 | 318,744 |
| HIGHCAPE CAPITAL, L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 29, 2024 | 0 |
| MILLS CHARLES RANDAL | Chief Executive Officer | Conversion of Exercise of derivative security | Dec 9, 2024 | 267,298 |
| WILLIAMS MICHELLE LEROUX | Officer | Conversion of Exercise of derivative security | Dec 9, 2024 | 68,399 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 9.47% | 2,864,947 | 12.55M | Sep 29, 2024 |
| AIGH Capital Management LLC | 8.30% | 2,510,442 | 11.00M | Sep 29, 2024 |
| SilverArc Capital Management, LLC | 5.44% | 1,645,808 | 7.21M | Sep 29, 2024 |
| Birchview Capital, LP | 4.37% | 1,321,215 | 5.79M | Sep 29, 2024 |
| Knollwood Investment Advisory, LLC | 3.09% | 934,617 | 4.09M | Sep 29, 2024 |
| Perkins Capital Management, Inc. | 2.83% | 856,552 | 3.75M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.08% | 327,330 | 1.43M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.54% | 163,575 | 716.46K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.33% | 100,339 | 439.48K | Oct 30, 2024 |
| World Funds Tr-Perkins Discovery Fund | 0.13% | 40,000 | 175.20K | Sep 29, 2024 |
| North Square Inv Tr-North Square Kennedy MicroCap Fund | 0.11% | 34,239 | 149.97K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 33,074 | 144.86K | Oct 30, 2024 |
